Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
November 3, 2015 8:00 AM EST
BAUDETTE, Minn., Nov. 3, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2015 and updated its financial guidance for 2015. The Company will host its earnings conference call this morning, November 3, 2015, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 59208657.
Arthur S. Przybyl, President and CEO, stated,
"We are pleased to report a strong third quarter, with increases over the prior year in revenue,... More
November 2, 2015 8:00 AM EST
BAUDETTE, Minn., Nov. 2, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.
Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of our authorized generic to Vancocin, which replaces the authorized generic previously on the market. This is the second of four generic products we plan to launch before the end of... More
